You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-459-ESGO UPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer

Article metrics

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-459-ESGO UPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer
Free

 

Online download statistics by month:

Online download statistics by month: October 2022 to April 2024

AbstractFullPdf
Oct 202215010
Nov 20225102
Dec 202244010
Jan 202371013
Feb 20232703
Mar 20234303
Apr 20232500
May 20234404
Jun 20231800
Jul 20232806
Aug 20234506
Sep 20231401
Oct 20232100
Nov 20232404
Dec 20233603
Jan 2024801
Feb 20241601
Mar 20243608
Apr 20241602
Total582077